<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83277">
  <stage>Registered</stage>
  <submitdate>17/10/2008</submitdate>
  <approvaldate>6/11/2008</approvaldate>
  <actrnumber>ACTRN12608000555358</actrnumber>
  <trial_identification>
    <studytitle>A study looking at the safety, tolerability absorption, breakdown, and elimination of SCH 900117 from the body in Healthy Volunteers and patients with Rheumatoid Arthritis.</studytitle>
    <scientifictitle>A Rising-Single-Dose and Multiple-Dose Safety, Tolerability, and Pharmacokinetic Study of SCH 900117 in Healthy Volunteers and in Subjects with Rheumatoid Arthritis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil Known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Rheumatoid Arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Part 1(Healthy Subjects Only): SCH 900117 12mg, 40mg, 120mg or 400mg. Single dose via subcutaneous injection on Day 1 (Subjects receive only 1 of the 4 possible rising dose levels or placebo. Subjects are randomised to receive active vs placebo). 
Part 2 (Rheumatoid Arthritis Patients Only): SCH 900117 400mg. Three subcutaneous doses of study drug or placebo over 3 months (Week 0, Week 4, Week 8). Subjects are randomised to receive either active or placebo.</interventions>
    <comparator>Placebo (normal saline).
Part 1: Single dose via subcutaneous injection on Day 1.
Part 2: Three doses subcutaneously over 3 months (Week 0, Week 4, Week 8).</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the Safety &amp; Tolerability of SCH 900117 in healthy subjects and patients with Rheumatoid Arthritis.
(Assessed via vital sign measurements, standard laboratory safety tests, urinalysis &amp;/or physical examinations)</outcome>
      <timepoint>Assessed throughout the study at each study visit . [Visit schedule Part 1: Daily visits up to Day 7 time point; Day 14; Biweekly until Week 16 (Day 112)] [Visit Schedule Part 2: Daily visits up to Day 7 time point; Day 14; Biweekly until Week 8; Week 9; Week 10; Week 12, Week 16; Monthly until week 24 (D168)]</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the Pharmacokinetics of SCH 900117 in healthy subjects and patients with Rheumatoid Arthritis.
(Assessed via pharmacokinetic blood sampling)</outcome>
      <timepoint>Assessed throughout the study at each study visit. [Visit Schedule Part 2: Daily visits up to Day 7 time point; Day 14; Biweekly until Week 8; Week 9; Week 10; Week 12, Week 16; Monthly until week 24 (D168)]</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Part 1-Healthy volunteers

Part 2-Rheumatoid Arthritis &gt;6mths
- &gt;=5 swollen &amp; tender joints</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>History of malignancy, Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Eligible subjects manually assigned an allocation number in sequential order by blinded study staff. Treatment dispensed in a blinded fashion by an unblinded pharmacist based on an unblinded master treatment allocation schedule.</concealment>
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/11/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Schering-Plough</primarysponsorname>
    <primarysponsoraddress>2000 Galloping Hill Road
Kenilworth, New Jersey 07033</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Schering-Plough</fundingname>
      <fundingaddress>2000 Galloping Hill Road
Kenilworth, New Jersey 07033</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Experiments in animals and research data in humans strongly suggests that IL-17A is involved in the formation of joint inflammation in rheumatoid arthritis. The primary purpose of this study is to establish the safety of  blocking the effects of IL-17A with SCH 900117 in healthy subjects and in patients with rheumatoid arthritis.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>22/09/2008</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Dr Peter Hodsman</name>
      <address>Nucleus Network
5th Floor Burnet Tower
89 Commercial Road
Melbourne, VIC 3004</address>
      <phone>+61 3 90768960</phone>
      <fax />
      <email>p.hodsman@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Dr Peter Hodsman</name>
      <address>Nucleus Network
5th Floor Burnet Tower
89 Commercial Road
Melbourne, VIC 3004</address>
      <phone>+61 3 90768960</phone>
      <fax />
      <email>p.hodsman@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jenny Lewis</name>
      <address>Schering-Plough
Level 4, 66 Waterloo Road
North Ryde, NSW 2113</address>
      <phone />
      <fax />
      <email>jenny.lewis@spcorp.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Peter Hodsman</name>
      <address>Nucleus Network 5th Floor Burnet Tower 89 Commercial Road Melbourne VIC 3004</address>
      <phone>+61 3 9076 8960</phone>
      <fax />
      <email>p.hodsman@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>